A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors

Local Institution - 0010, Lausanne

Local Institution - 0009, Chur

Local Institution - 0011, Zurich

Local Institution - 0001, Philadelphia

Local Institution - 0007, Madrid

Local Institution - 0008, Madrid

Local Institution - 0004, Nashville

Local Institution - 0012, St Louis

Local Institution - 0005, Boston

Local Institution - 0002, Hackensack

Local Institution - 0014, Edmonton

Local Institution - 0006, Hamilton

Local Institution - 0003, Toronto